Boehringer Ingelheim and IBM collaborate to advance generative AI and foundation models for…
Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development…
Read More...
Read More...